0001104659-21-150527.txt : 20211216
0001104659-21-150527.hdr.sgml : 20211216
20211216161622
ACCESSION NUMBER: 0001104659-21-150527
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211213
FILED AS OF DATE: 20211216
DATE AS OF CHANGE: 20211216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rombotis Spiro George
CENTRAL INDEX KEY: 0001357396
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50626
FILM NUMBER: 211497965
MAIL ADDRESS:
STREET 1: C/O CYCLACEL PHARMACEUTICALS, INC.
STREET 2: 200 CONNELL DRIVE, SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
FORMER NAME:
FORMER CONFORMED NAME: Rombotis Spiro
DATE OF NAME CHANGE: 20060324
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001130166
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911766850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
BUSINESS PHONE: 908-517-7330
MAIL ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
FORMER COMPANY:
FORMER CONFORMED NAME: XCYTE THERAPIES INC
DATE OF NAME CHANGE: 20001218
4/A
1
tm2135616d1_4a.xml
OWNERSHIP DOCUMENT
X0306
4/A
2021-12-13
2021-12-15
0
0001130166
Cyclacel Pharmaceuticals, Inc.
CYCC
0001357396
Rombotis Spiro George
C/O CYCLACEL PHARMACEUTICALS, INC.,
200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS
NJ
07922
1
1
0
0
President and CEO
Stock Option (right to buy)
3.45
2021-12-13
4
A
0
190000
0
A
2031-12-13
Common Stock
190000
190000
D
These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
These securities were granted as part of the Issuer's annual compensation review to executive officers.
This Form 4 is being amended to correct a typographical error in the number of shares of Common Stock underlying the options granted to the reporting person on December 13, 2021. 190,000 shares of Common Stock underlie the granted options.
/s/ Spiro Rombotis
2021-12-16